OVERVIEW

Exploring New Evidence in the Treatment of Post-Traumatic Stress Disorder (PTSD) is organized by College of Psychiatric and Neurologic Pharmacists (CPNP).

Activity Dates: 05/16/2019 - 04/09/2022

Target Audience:
This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

ACPE Contact Hours: 1

Session Summary:
The DSM-5 was published in 2013 with a significant change in the categorization of PTSD, from Anxiety disorder to Trauma/Stressor related disorder, based on a better understanding of the pathophysiology of the disorder. PTSD can be a disabling condition and can occur in not only war survivors, but also survivors of child abuse, violence, motor vehicle accidents, and world and national disasters to name a few. Advances in the understanding of the pathophysiology of PTSD have led to the recognition of multiple changes in neurophysiology related to PTSD which are new targets for novel therapies. In this session, participants will enhance their understanding of the pathophysiology and most up to date results of trials to enhance treatment recommendations when a standard pharmacotherapy is ineffective.

Learning Objectives:
• Describe the current understanding of the pathophysiology of PTSD.
• Provide an overview of evidence-based pharmacotherapies for PTSD.
• Explain the quality and consistency of current trials utilizing novel pharmacotherapeutic approaches to treating PTSD.

Additional details will be posted as soon as they are available.